Orchestra BioMedvsThermo Fisher Scientific

OBIO and TMO stock compared: price, dividend, valuation and results, from SEC filings.

OBIO

Orchestra BioMed Holdings, Inc.

$7.18

Value $565M

-0.97%
OBIO's page

TMO

Thermo Fisher Scientific Inc

$692.91

Value $257B

-1.01%
TMO's page

Orchestra BioMed (OBIO) has a market value of $565M and Thermo Fisher Scientific (TMO) $257B. Over the last year, with dividends, OBIO moved +82.2% and TMO +20.2%. Dividend yield: OBIO none, TMO 0.27%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    OBIO$565M

    TMO$257B

    TMO is 456 times OBIO

  • Revenue, 12 months

    OBIO$31M

    TMO$47.4B

    TMO is 1,517 times OBIO

  • Net income, 12 months

    OBIO-$57M

    TMO$7.1B

  • Operating margin

    OBIO-195.4%

    TMO17.9%

    213.3 points apart

  • ROIC

    OBIO-95.5%

    TMO8.2%

    103.7 points apart

  • P/E

    OBIO–

    TMO36.4

  • Dividend yield

    OBIO0.0%

    TMO0.3%

    0.3 points apart

  • 5-year return

    OBIO-27.3%

    TMO+11.2%

    38.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

OBIO-27.3%

TMO+11.2%

10020020222023202420252026
Returns by period
PeriodOBIOWith dividendsTMOWith dividends
1 year since November 14, 2025+82.2%Price +82.2%+20.2%Price +19.8%
3 years since November 16, 2023+2.9%+0.9% a yearPrice +2.9%+48.1%+14.0% a yearPrice +46.7%
5 years since November 15, 2021-27.3%-6.2% a yearPrice -27.3%+11.2%+2.1% a yearPrice +9.6%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

OBIOOrchestra BioMedTMOThermo Fisher Scientific

Valuation

OBIOTMO
Valuation
Price$7.18$692.91
Market value$565M$257B
Enterprise value (EV)$484M$293B
P/E–36.4
P/E, 5-year median–32.7
P/B72.64.7
EV/EBIT–34.6
Free cash flow yield–2.9%

Results and growth

OBIOTMO
Results and growth
Revenue, 12 months$31M$47.4B
Net income, 12 months-$57M$7.1B
Free cash flow, 12 months-$64M$7.6B
Earnings per share, 12 months-$0.75$18.96
Revenue growth, year on year1,169.2%3.9%
Revenue growth a year, past+111.6%over 3 years+6.7%over 5 years
EPS growth a year, past–+2.1%over 5 years

Margins and returns on capital

OBIOTMO
Margins and returns on capital
Gross margin99.6%–
Operating margin-195.4%17.9%
Net margin-182.5%14.9%
ROIC-95.5%8.2%
ROE-172.0%13.4%

Balance sheet

OBIOTMO
Balance sheet
Cash$102M$6.1B
Total debt$22M$41.4B
Net debt / EBITDA–3.7
Interest cover–5.5×

Dividends and buybacks

OBIOTMO
Dividends and buybacks
Dividend yield–0.3%
Dividend per share, 12 months–$1.84
Dividend growth a year, past–+14.3%over 5 years
Buyback yield–1.2%
Shareholder yield–1.4%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: OBIO or TMO

Didn't find what you were looking for?

Ask us
Which is bigger, Orchestra BioMed or Thermo Fisher Scientific?

By market value, Thermo Fisher Scientific ($257B) is about 455.5 times Orchestra BioMed ($565M), at today's prices.

How did OBIO and TMO stock do over the last 5 years?

Since November 15, 2021, OBIO's price moved -27.3% and TMO's +9.6%. With dividends: OBIO -27.3% (-6.2% a year), TMO +11.2% (+2.1% a year). Past returns do not predict future ones.

Which pays the higher dividend, OBIO or TMO?

The dividend yield at today's price is none for Orchestra BioMed and 0.27% for Thermo Fisher Scientific. Over the last twelve months they paid – and $1.84 per share.

Which has the higher profit margins, Orchestra BioMed or Thermo Fisher Scientific?

Over the last twelve months, the net margin was -182.5% for Orchestra BioMed and 14.9% for Thermo Fisher Scientific, and the operating margin -195.4% and 17.9%. Revenue was $31M and $47.4B.

Which is the better investment, Orchestra BioMed or Thermo Fisher Scientific?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.